Abbott India Ltd.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. This change reflects evolving market perceptions and has significant implications for investors assessing the stock’s price attractiveness relative to its historical and peer benchmarks.

Abbott India Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 September 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 19 September 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

The Sensex edged lower by 0.03% on 18 Sep 2026, while Abbott India Ltd. surged 5.34%, outperforming its Pharmaceuticals & Biotechnology sector by 4.7 percentage points. This sharp single-session gain rewrites the short-term narrative for the mid-cap stock, which has now reclaimed ground above all its key moving averages.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 1.24%, the stock’s technical indicators present a complex picture, with some signals suggesting cautious optimism while others maintain a bearish undertone. This article analyses the recent technical parameter changes, key momentum indicators, and the stock’s relative performance against the broader market.

The 50-day moving average has crossed above the 200-day moving average for Abbott India Ltd. on 11 Jun 2026, signalling a golden cross. Yet, this technical event arrives amid a patchwork of conflicting indicators and subdued price momentum, raising questions about the signal’s reliability in the current context.

Abbott India Ltd. has reached a new 52-week low of Rs. 25,143.45 on 11 September 2026, reflecting a notable decline in its stock price amid broader market weakness and sectoral pressures.

For the third consecutive session, Abbott India Ltd. has seen its share price decline, culminating in a fresh 52-week low of Rs 25,147.5 on 09 Jun 2026. This drop comes amid a broader market downturn, but the stock’s underperformance relative to its sector and benchmark indices highlights company-specific pressures.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a revision of its MarketsMOJO grade from Sell to Hold. Despite this upgrade, the stock faces bearish pressures across multiple technical indicators, reflecting a cautious outlook amid recent price declines and mixed trend signals.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 7 September 2026. This change reflects a nuanced improvement across multiple parameters including technical indicators, valuation metrics, financial trends, and overall quality, signalling a cautious but positive outlook for investors amid mixed market performance.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day decline of 0.67%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse amid broader market volatility.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s Mojo Grade was downgraded from Hold to Sell on 12 May 2026, reflecting deteriorating technical conditions amid a price decline of 1.67% on 1 September 2026. This article analyses the recent technical parameter changes, price momentum, and comparative performance against the Sensex to provide a comprehensive view for investors.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions amid sector-wide valuation trends and peer comparisons, impacting the stock’s price attractiveness for investors.

Abbott India Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Abbott India Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a strong long-term return profile, recent price action and technical parameters suggest mounting pressure on the stock, prompting a downgrade in its mojo grade from Hold to Sell as of 12 May 2026.